Toronto, Canada
SQI Diagnostics is a precision medicine company focused on discovering, developing, and commercializing innovative rapid diagnostic testing for healthcare providers, patients, and consumers worldwide. The company's proprietary advanced diagnostics target organ transplant, autoimmune disease, and COVID-19 testing, including the developmental direct-to-consumer COVID-19 HOME Antibody Test, the RALI-dx™ COVID-19 Severity Triage Test, and the COVID-19 RALI-fast™ Severity Triage Point-of-Care (POC) Test. Founded in 1999 and headquartered in Canada, SQI Diagnostics is at the forefront of leveraging cutting-edge technology to create innovative diagnostics, aligning with their slogan, "Our commitment is to improve lives by leveraging our cutting-edge technology to create innovative diagnostics."
The company recently secured a $10.00M Post-IPO Equity investment on 13 March 2023, signaling investor confidence in their technology and market potential. This investment will likely accelerate the company's growth and expansion efforts, further establishing its position in the Biotechnology industry. While the specific details of the investors for the last investment are not available, the substantial funding indicates that SQI Diagnostics is an attractive prospect for potential venture capital partners seeking opportunities in the rapidly evolving healthcare and diagnostics sector.
